Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

EBR Systems, Inc.

EBRCZOTCEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On April 9, 2026 (Australia time), EBR Systems, Inc. (the “Company”) issued a press release announcing the Company’s commercial progress, as well as preliminary financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.…

Filed Apr 9, 2026Accepted Apr 8, 2026, 7:06 PM EDTCIK 1347123Accession 0001214659-26-004488
Share

Company context

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

Current securities

Recent company filings

  1. S-8 filingAug 24, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsAug 24, 2026
  3. Submission of Matters to a Vote of Security HoldersAug 20, 2026
  4. 10-Q filingAug 11, 2026
  5. DEFA14A filingJul 9, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition On April 9, 2026 (Australia time), EBR Systems, Inc. (the “Company”) issued a press release announcing the Company’s commercial progress, as well as preliminary financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The Company has not yet completed its financial close process for the quarter ended March 31, 2026. These estimates of the Company’s preliminary financial results presented in the press release are preliminary, unaudited and are subject to change upon completion of the Company’s financial statement closing procedures and the review of the Company’s consolidated financial statements. The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99_1.htm

EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 9 April 2026 ────────────────────────────────────── EBR Reports Strong Q1 2026 Growth in Commercial Cases Key Highlights Robust commercial momentum continued through Q1 2026 with case volumes more than doubling from Q4 2025 ─────────────────────────────────────────────────────────────────────────────── The WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total implants across the pilot phase and Limited Market Release to 71 ─────────────────────────────────────────────────────────────────────────────────────────────────────── EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments The Limited Market Release continued to advance in Q1 2026 with an additional 16 purchase agreements signed and 22 additional physicians trained to support the adoption of WiSE ────────────────────────────────────────────────────────────────────────────────────────────────────── Investor webinar on Friday 10 April 2026 at 09:00am AEST ─…

Open exhibit ↗